Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
i`

Application Number		10573722
Filing Date		2006-03-27
First Named Inventor Adam		S. LEITCH
Art Unit		2131
Examiner Name		
Attorney Docket Number		GB030165

	U.S.PATENTS					Remove				
Examiner Initial*	Examiner Cite No Patent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document				Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear					
	1	5243653		1993-09-07	MALEK ET A	L				
	2	5802453		1998-09-01	KUROKI ET A	AL.				
	3	4853962		1989-08-01	BROCKMAN					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n information	please click the	Add button.		Add		Т
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number Kind Code ¹ Date Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev				
	1	20020034300	A1	2002-03-21	THUVESHOL	MEN ET AL				
	2	20020164029	A1	2002-11-07	JIANG					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication citat	ion information	please click the Ad	d button	Add		_
				FOREIGN PA	ATENT DOCUM	MENTS		Remove		
									umns,Lines	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

GB

2369753

Application Number		10573722
Filing Date		2006-03-27
First Named Inventor Adam		S. LEITCH
Art Unit		2131
Examiner Name		
Attorney Docket Numb	or	GB030165

2002-06-05 SIMOÇO INTER LTD

		2	2369753	GB	B1	2003-02-26	SIMOCO INTER LTD		
		3	1089487	EP	A2	2001-04-04	ERICSSON INC		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), whileher, city and/or country waters whileher.								Ţ5

A1

| WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY PCT/IB2004051840

	EXAMINER SIGNATURE						
Examiner Signature	Date Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at Invest,USETO.GD(yr arWEP 901.04. Esters dote that issued the document, by the Noveletce (WIPO Standard ST3.). "For Explaneme patent for counters, the indication of the year of the register of the Empiror many precise the serial results of the patent for supplied of the Empiror many precise the serial results of the patent for supplied of the Empiror many precise the serial results of the patent for supplied on the Empiror many precise the serial results of the patent for supplied in the patent precise the serial results or at attached.

Incl of occurrent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Deplicated is to place a check mark here if English languages the resultation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10573722
Filing Date		2006-03-27
First Named Inventor Adam		S. LEITCH
Art Unit		2131
Examiner Name		
Attorney Docket Number		GB030165

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(vi).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

orno de agrada.								
Signature	/Paul Im/	Date (YYYY-MM-DD)	2007-09-19					
Name/Print	Paul Im	Registration Number	50.418					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.